Profile
Delphine Dumas is currently Chief Pharmaceutical Officer & Quality Director at Advicenne SA since 2025.
Former positions include Chief Pharmaceutical Officer at NOVARTIS GENE THERAPIES FRANCE S.A.S., Manager-Quality Assurance at Vifor France SASU from 2011 to 2015, Manager-Quality Assurance at Eurodep from 2006 to 2010, and Chief Pharmaceutical Officer at Kyowa Kirin Pharma SAS from 2015 to 2020.
Education includes a doctorate from Universite Clermont Auvergne and a graduate degree from Université Paris-Saclay.
Delphine Dumas active positions
| Companies | Position | Start |
|---|---|---|
| ADVICENNE | Chief Tech/Sci/R&D Officer | 2025-08-31 |
Former positions of Delphine Dumas
| Companies | Position | End |
|---|---|---|
Kyowa Kirin Pharma SAS
Kyowa Kirin Pharma SAS Medical DistributorsDistribution Services Wholesales pharmaceutical products | Corporate Officer/Principal | 2019-12-31 |
Vifor France SASU
Vifor France SASU BiotechnologyHealth Technology Engages in research and development of pharmaceutical products | Corporate Officer/Principal | 2014-12-31 |
Training of Delphine Dumas
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 5 |
|---|---|
Advicenne SA
Advicenne SA Pharmaceuticals: GenericHealth Technology Develops and markets pediatric drugs | Health Technology |
Universite Clermont Auvergne
Universite Clermont Auvergne Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Université Paris-Saclay
Université Paris-Saclay Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Kyowa Kirin Pharma SAS
Kyowa Kirin Pharma SAS Medical DistributorsDistribution Services Wholesales pharmaceutical products | Distribution Services |
Vifor France SASU
Vifor France SASU BiotechnologyHealth Technology Engages in research and development of pharmaceutical products | Health Technology |
- Stock Market
- Insiders
- Delphine Dumas
















